GenNext Technologies Appoints Dr. Lisa Jones of UCSD to the Role of Chief Science Officer (CSO)
Professor Jones will lead the development of protein footprinting technology to study protein interactions of in vivo membrane proteins.
HALF MOON BAY, Calif. – January 11, 2023 – Life Science Newswire – With ambitious plans to expand the reach and impact of their Flash Oxidation (Fox™) Protein Footprinting System beyond in vitro proteins, GenNext Technologies, Inc. (GenNext) is adding to the strength of their leadership team with the selection of Dr. Lisa Jones as the company’s new CSO. Transitioning from her role on the company’s Scientific Advisory Board, GenNext will benefit from Dr. Jones’ experience as the world-recognized pioneer of in-cell and whole-organism Fast Photochemical Oxidation of Proteins (FPOP).
In the Department of Chemistry and Biochemistry at UCSD, the Jones Lab is a structural proteomics group that uses biochemical, analytical, and biophysical approaches coupled with mass spectrometry to identify protein interactions. The Jones lab has further expanded FPOP for in vivo analysis in C. elegans, an animal model for human disease.
As CSO, Dr. Jones will shape the scientific strategy of GenNext and lead its R&D efforts aimed at investigating the protein interactions of membrane proteins, the largest class of drug targets. By developing a new way to study this important biological process, GenNext will enable biopharmaceutical researchers to perform in-cell monitoring of proteins in their native cellular environment, without the challenges associated with purifying these types of proteins.
Profession Jones commented, “I’ve worked my entire career to advance the science and technology of FPOP. By stepping-up to the GenNext leadership team, I am realizing a long-held ambition to advance the technology for protein characterization. I have been advising this inventive team for several years, and now I can help direct the development of new technologies that have never been seen before. Truly a career-changing opportunity for me.”
Scot Weinberg, CEO of GenNext said, “I have admired and respected Lisa for many years, and I am thrilled that she will sit on the company’s leadership team. Her vast scientific research experience, along with her ability to innovate and break through boundaries, will be sure to help us realize our goal of helping biopharmaceutical companies discover and produce safer and more effective biologics.”
For more information, please see our website at www.gnxtech.com.
About GenNext Technologies
Located in the San Francisco Bay Area, GenNext Technologies, Inc., is a growth-stage company that provides instrumentation, software, and services to pharmaceutical researchers investigating biopharmaceutical structure, interactions, folding, aggregation, formulation, and delivery. Our powerful, compact, and cost-effective platform enables researchers to conduct reproducible Higher Order Structure experiments quickly, easily, and safely. We help our customers accelerate biopharmaceutical development, while improving therapeutic efficacy and safety. Ultimately, our mission is to enable structural biology researchers to discover and develop drug therapies that improve human health.